Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy

30 Oct 2026 0 comments

Definitions of disease progression in ATTR-CM rely on clinical, biomarker, and functional measures of downstream manifestations of disease rather than the biological processes targeted by new therapies.
JACC

Source: Medscape Neurology Published 30 Oct 2026 Imported 30 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment